What is it and how is it used?
Immunosuppressants.
CellCept tablets are used to prevent your body rejecting a transplanted kidney, heart or liver. CellCept is used together with other medicines known as ciclosporin and corticosteroids.
Ad
Substance(s) | Mycophenolic acid |
Admission country | United Kingdom |
Manufacturer | Roche Registration Ltd. |
Narcotic | No |
ATC Code | L04AA06 |
Pharmacological group | Immunosuppressants |
Drug | Substance(s) | Authorisation holder |
---|---|---|
Myfenax 500 mg film-coated tablets | Mycophenolic acid | Teva Pharma B.V. |
CellCept 500 mg powder for concentrate for solution forinfusion | Mycophenolic acid | Roche Registration Ltd. |
CellCept 1 g/5 ml powder for oral suspension | Mycophenolic acid | Roche Registration Ltd. |
Mycophenolate mofetil Teva 250 mg hard capsules | Mycophenolic acid | Teva Pharma B.V. |
Myfenax 250 mg hard capsules | Mycophenolic acid | Teva Pharma B.V. |
Immunosuppressants.
CellCept tablets are used to prevent your body rejecting a transplanted kidney, heart or liver. CellCept is used together with other medicines known as ciclosporin and corticosteroids.
Ad
You should inform your doctor immediately:
CellCept reduces your body?s defence mechanism. Because of this, there is an increased risk of skin cancer. Therefore you should limit your exposure to sunlight and UV light by wearing appropriate protective clothing and using a sunscreen with a high protection factor.
Taking other medicines:
Please inform your doctor or pharmacist if you are taking, or have recently taken, any other medicines, even those not prescribed.
If you answer yes to any of the following questions talk to your doctor before you start to take CellCept:
Taking food and drink has no influence on your treatment with CellCept.
Use of CellCept during pregnancy may cause miscarriage or damage to your unborn baby (abnormal development of ears for example).
If you plan to become pregnant, discuss with your doctor alternative medicines to best prevent rejection of your transplanted organ. In certain situations, you and your doctor may decide that the benefits of taking CellCept for your health are more important than the possible risks to your unborn baby.
If you become pregnant while taking CellCept, do not stop taking it, but tell your doctor about your pregnancy as soon as possible.
Do not take CellCept if you are:
Tell your doctor straight away if:
You must always use an effective method of birth control:
You should talk to your doctor about the most suitable methods for birth control for you based on your individual situation.
Women who are capable of becoming pregnant must have a negative pregnancy test BEFORE starting treatment with CellCept.
You are a woman who is not capable of becoming pregnant if any of the following applies to you:
CellCept has not been shown to impair your ability to drive or operate machinery.
Ad
Always take CellCept exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure. The usual way to take CellCept is as follows:
Adults:
The first dose will be given within 72 hours after the transplant operation. The recommended dailydose is 4 tablets (2 g of the active ingredient) taken as 2 separate doses. This means taking 2 tablets in the morning then 2 tablets in the evening.
Children (aged 2 to 18 years):
The dose given will vary depending on the size of the child. Your doctor will decide the most appropriate dose based on body surface area (height and weight). The recommended dose is 600 mg/m 2 taken twice a day.
Adults:
The first dose will be given within 5 days following the transplant operation. The recommended daily dose is 6 tablets (3 g of the active ingredient) taken as 2 separate doses. This means taking 3 tablets in the morning then 3 tablets in the evening.
Children:
No data are available to recommend the use of CellCept in children who have received a heart transplant.
Adults:
The first dose of oral CellCept will be given to you at least 4 days after the transplant operation and when you are able to swallow oral medications. The recommended daily dose is 6 tablets (3 g of the active ingredient) taken as 2 separate doses. This means taking 3 tablets in the morning and then 3 tablets in the evening.
Children:
No data are available to recommend the use of CellCept in children who have received a liver transplant.
Swallow your tablets whole with a glass of water. Do not break or crush them.
Treatment will continue for as long as you need immunosuppression to prevent you rejecting your transplanted organ.
If you take more tablets than you have been told to take, or if someone else accidentally takes your medicine, immediately see a doctor or go to a hospital straight away.
If you forget to take CellCept:
If you forget to take your medicine at any time, take it as soon as you remember, then continue to take it at the usual times.
If you stop taking CellCept:
Stopping your treatment with CellCept may increase the chance of rejection of your transplanted organ. Do not stop taking your medicine unless your doctor tells you to.
If you have any further questions on the use of this product, ask your doctor.
Ad
Like all medicines, CellCept can have side effects, although not everybody gets them. Some of the more usual problems are diarrhoea, fewer white cells and/or red cells in your blood, infection and vomiting. Your doctor will do regular blood tests to monitor any changes in the number of your blood cells or changes in the levels of any of the substances carried in your blood, e.g. sugar, fat, cholesterol. Children may be more likely than adults to have side effects such as diarrhoea, infections, fewer white cells and fewer red cells in the blood.
CellCept reduces your body?s own defence mechanisms to stop you rejecting your transplanted kidney, heart or liver. Consequently your body will not be as good as normal at fighting infections. So if you are taking CellCept you may therefore catch more infections than usual, such as infections of the brain, skin, mouth, stomach and intestines, lungs and urinary tract. As can happen in patients taking this type of medicine, a very small number of CellCept patients have developed cancer of the lymphoid tissues and skin.
General unwanted effects affecting your body as a whole could include hypersensitivity (such as anaphylaxis, angioeodema), fever, lethargy, difficulty in sleeping, pains (such as abdominal, chest, joint/muscle, pain on passing urine), headache, flu symptoms and swelling.
Other unwanted effects may include:
Disorders of the skin such as acne, cold sores, shingles, skin growth, hair loss, rash,itching.
Urinary disorders such as kidney problems or the urgent need to pass urine.
Disorders of the digestive system and mouth such asconstipation, nausea, indigestion, pancreas inflammation, intestinal disorders including bleeding, inflammation of the stomach, liver problems, inflammation of the colon, loss of appetite, flatulence, swelling of the gums and mouth ulcers.
Disorders of the nerves and senses such as convulsions, tremor, dizziness, depression, drowsiness, numbness, muscle spasms, anxiety, changes in thinking or mood.
Metabolic, blood and vascular disorders such as weight loss, gout, high blood sugar, bleeding, bruises, change in blood pressure, abnormal heart beat and dilation of blood vessels may be seen.
Disorders of the lungs such aspneumonia, bronchitis, shortness of breath, cough, fluid on the lungs/chest cavity, sinus problems.
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet whilst you are taking CellCept, please tell your doctor or pharmacist. However, do not stop taking your medicine unless you have discussed this with your doctor first.
Ad
Keep out of the reach and sight of children.
Do not use the tablets after the expiry date stated on the carton (EXP).
Do not store above 30 °C. Keep in outer carton in order to protect from light.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.
Ad
CellCept tablets:
microcrystalline cellulose
polyvidone (K-90)
croscarmellose sodium
magnesium stearate
Tablet coating:
hydroxypropyl methylcellulose
hydroxypropyl cellulose
titanium dioxide (E171)
polyethylene glycol 400
indigo carmine aluminium lake (E132)
red iron oxide (E172)
CellCept 500 mg tablets 1 carton contains 50 tablets in blister packs of 10 1 carton contains 150 tablets in blister packs of 10
Tablets:
CellCept tablets: lavender coloured caplet-shaped tablet, engraved with "CellCept 500" on one side and "Company logo" on the other.
Roche Registration Limited
6 Falcon Way
Shire Park
Welwyn Garden City
AL7 1TW
United Kingdom
Manufacturing Authorisation holder responsible for batch release
Roche Pharma AG, Emil Barell Str. 1, 79639 Grenzach Wyhlen, Germany.
For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder:
LuxembourgLuxemburg Voirsiehe BelgiqueBelgien BelgiëBelgiqueBelgien N.V. Roche S.A. TélTel 32 0 2 525 82 11
359 2 818 44 44 Magyarország Roche Magyarország Kft. Tel 36 - 23 446 800
Malta See United Kingdom eská republika Roche s. r. o. Tel 420 - 2 20382111
Danmark Roche as Tlf 45 - 36 39 99 99 Nederland Roche Nederland B.V. Tel 31 0 348 438050
Deutschland Roche Pharma AG Tel 49 0 7624 140 Norge Roche Norge AS Tlf 47 - 22 78 90 00
Eesti Roche Eesti OÜ Tel 372 - 6 177 380 Österreich Roche Austria GmbH Tel 43 0 1 27739
Roche Hellas A.E. 30 210 61 66 100 Polska Roche Polska Sp.z o.o. Tel 48 - 22 345 18 88
España Roche Farma S.A. Tel 34 - 91 324 81 00 Portugal Roche Farmacêutica Química, Lda Tel 351 - 21 425 70 00
France Roche Tél 33 0 1 46 40 50 00 România Roche România S.R.L. Tel 40 21 206 47 01
Ireland Roche Products Ireland Ltd. Tel 353 0 1 469 0700 Slovenija Roche farmacevtska druba d.o.o. Tel 386 - 1 360 26 00
Slovenská republika Roche Slovensko, s.r.o. Tel 421 - 2 52638201 Ísland Roche as co Icepharma hf Sími 354 540 8000
Italia Roche S.p.A. Tel 39 - 039 2471 SuomiFinland Roche Oy PuhTel 358 0 10 554 500
K .. . 357 - 22 76 62 76 Sverige Roche AB Tel 46 0 8 726 1200
Latvija Roche Latvija SIA Tel 371 - 6 7039831 United Kingdom Roche Products Ltd. Tel 44 0 1707 366000
UAB ?Roche Lietuva?
Tel: +370 5 2546799
This leaflet was last approved on {MM/YYYY}
Ad
Substance(s) | Mycophenolic acid |
Admission country | United Kingdom |
Manufacturer | Roche Registration Ltd. |
Narcotic | No |
ATC Code | L04AA06 |
Pharmacological group | Immunosuppressants |
Ad